Seval Ozkan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seval Ozkan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Azeddine Atfi
Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
2 shared publications - Allyn Austin Bryan
Richmond Department of Veterans Affairs, 1201 Broad Rock Blvd, Richmond Va, USA, 23249
1 shared publication Celine Prunier
Centre de Recherche Saint‐Antoine, CRSA Inserm Sorbonne Universités Paris France
1 shared publication- Celine Prunier
Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA 3 , Paris, France
1 shared publication - Creighton Friend
Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University 1 , Richmond, VA, USA
1 shared publication - Deanna Campbell
Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University 1 , Richmond, VA, USA
1 shared publication
Latest Publications
- Open Access
- 24 February 2023
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 222 (4)
Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer
The transcription factor Prdm16 functions as a potent suppressor of transforming growth factor-beta (TGF-β) signaling, whose inactivation is deemed essential to the progression of pancreatic ductal adenocarcinoma (PDAC). Using the KrasG12D-based mouse model of human PDAC, we surprisingly found that ablating Prdm16 did not block but instead accelerated PDAC formation and progression, suggesting that Prdm16 might function as a tumor suppressor in this malignancy. Subsequent genetic experiments showed that ablating Prdm16 along with Smad4 resulted in a shift from a well-differentiated and confined neoplasm to a highly aggressive and metastatic disease, which was associated with a striking deviation in the trajectory of the premalignant lesions. Mechanistically, we found that Smad4 interacted with and recruited Prdm16 to repress its own expression, therefore pinpointing a model in which Prdm16 functions downstream of Smad4 to constrain the PDAC malignant phenotype. Collectively, these findings unveil an unprecedented antagonistic interaction between the tumor suppressors Smad4 and Prdm16 that functions to restrict PDAC progression and metastasis.
- 24 February 2023
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 222 (4)
Open AccessAntagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer
The transcription factor Prdm16 functions as a potent suppressor of transforming growth factor-beta (TGF-β) signaling, whose inactivation is deemed essential to the progression of pancreatic ductal adenocarcinoma (PDAC). Using the KrasG12D-based mouse model of human PDAC, we surprisingly found that ablating Prdm16 did not block but instead accelerated PDAC formation and progression, suggesting that Prdm16 might function as a tumor suppressor in this malignancy. Subsequent genetic experiments showed that ablating Prdm16 along with Smad4 resulted in a shift from a well-differentiated and confined neoplasm to a highly aggressive and metastatic disease, which was associated with a striking deviation in the trajectory of the premalignant lesions. Mechanistically, we found that Smad4 interacted with and recruited Prdm16 to repress its own expression, therefore pinpointing a model in which Prdm16 functions downstream of Smad4 to constrain the PDAC malignant phenotype. Collectively, these findings unveil an unprecedented antagonistic interaction between the tumor suppressors Smad4 and Prdm16 that functions to restrict PDAC progression and metastasis.
- Open Access
- 31 May 2019
- Published by Springer Nature in The EMBO Journal
- Vol. 38 (13) , e101067
TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 31 May 2019
- Published by Springer Nature in The EMBO Journal
- Vol. 38 (13) , e101067
Open AccessTGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.